heartdiseasefacts.com
[ad_1]
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to the University of Iowa Research Foundation (UIRF) for U.S. Application No. 17,857,723, entitled Compositions and Methods for Detecting Predisposition to Cardiovascular Disease. UIRF’s Diagnostics Holdings is the co-invention of Cardio Diagnostics’ founders, his CEO Meesha Dogan, Ph.D., and his CMO Robert Philibert, M.D. Cardio Diagnostics announced that this is his second U.S. patent to be issued within this patent family. Patents in this patent family have also been issued in the European Union, China, India, and Australia.
These patents relate to the company’s integrated epigenetic-genetic engine technology developed to assess and stratify cardiovascular risk and identify novel biomarkers and pathways important in the development of cardiovascular disease. It is something.
“The issuance of our latest patents further protects our precision technologies and solutions that leverage the power of advanced genomics, advanced epigenomics, and artificial intelligence for risk assessment, diagnosis, treatment, management, and monitoring of cardiovascular disease. “It helps us do that,” Dougan said. “Our precision medicine solutions enable healthcare professionals, from patients, clinicians, payers to employers, to make data-driven clinical, personal, and business decisions to improve the human impact of heart disease. This will help you avoid damage and financial burden.”
Cardio Diagnostics products include:
Epi + Gene CHD: An integrated genetic-epigenetic blood test to assess the 3-year risk of coronary heart disease (CHD) events, specifically heart attack and CHD-related sudden death.
Precision CHD: An integrated genetic and epigenetic blood test to aid in the diagnosis of coronary heart disease.
heart risks: Enabling data-driven, multi-stakeholder collaboration between patients, innovative providers, health plans, employers, and government agencies to advance heart disease risk stratification and advance early prevention and intervention. A cardiovascular disease risk intelligence platform that powers.
CardioInnovate360: Three pivotal areas: identification of novel biomarkers and pathways important in the development of CVD, patient stratification to increase the effectiveness of clinical trials, and development of non-invasive and scalable post-market surveillance and companion diagnostic tests. A biopharmaceutical research solution that provides advanced functionality.
Related article
-
Casgevy, a cell-based gene therapy for transfusion-dependent beta-thalassemia utilizing CRISPR/Cas9 technology, has been approved by the FDA following submissions through the Fast Track and Regenerative Medicine Advanced Therapies (RMAT) programs.
-
Behavioral health providers were excluded from the HITECH Act of 2009, contributing to large disparities in EHR implementation between mental and physical health providers. The Behavioral Health Information Technology (BHIT) Coordination Act could help improve this, but regulatory and social…
-
Massive amounts of data are collected throughout the surgical continuum, but can chief medical officers and perioperative leaders use it to drive clinical, operational, and financial improvements? Embrace data-driven surgery By doing so, HCO…
-
CVS Health has entered into a definitive agreement to acquire Signify Health, a network of more than 10,000 physicians, nurses and physician assistants who provide home visits.
[ad_2]
Source link
